Evolus, Inc. Common Stock (EOLS) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

Evolus, Inc. Common Stock

NasdaqGM•Healthcare•Drug Manufacturers - Specialty & Generic

$9.30+0.25(0.03%)Market closed

Market Cap

$528.09M

P/S

1.7x

Evolus, Inc., a performance beauty company, delivers products in the cash-pay aesthetic market in the United States, Canada, Europe, and Australia. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults; and Evolysse, a collection of injectable hyaluronic acid gels, which includes various products, such as mid face, nasolabial folds, lips and eyes. The company was incorporated in 2012 and is headquartered in Newport Beach, California.

How this company scores

WeakMetricSide Score: 50/100

Grade capped at D — Negative equity — the balance sheet is insolvent. Strongest: Growth (19/25); weakest: Balance Sheet & Red Flags (4/25).

Profitability17/25

Growth19/25

Balance Sheet & Red Flags4/25

Cash & Earnings Quality10/25

Strengths

Long cash runwayProfit converts from growthConsistent growthImproving margins

Grade capped at D

Negative equity — the balance sheet is insolvent.
Interest coverage below 1× (-1.1x) — earnings cannot cover interest.

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/S · 1.7x5y range 0.9x – 5.1x

Currently below its 20-quarter median.

P/B · 125.0x5y range 4.0x – 173.7x

Currently above its 11-quarter median.

Watch items

Data-driven signals worth keeping an eye on across the last 8 quarters

High Risk

Margin Pressure

Red Flag

The company posted negative operating margins in recent quarters — core operations are unprofitable.

Earnings Quality

Red Flag

Free cash flow has been negative in 6 of the last 8 quarters — earnings are not translating to cash.

Price & Volume

Market Cap $528.09M

Metrics at a Glance

as of June 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue: $316.49M
Q. Revenue: $84.08M
TTM EBITDA: $-13.02M
TTM Op. Income: $-18.67M
Q. Op. Income: $-4.54M
TTM Net Income: $-34.33M
Q. Net Income: $-8.05M
EPS: $-0.12
Shares Out.: $65.93M

$316.49M in TTM revenue grew 13.9% YoY, reaching $84.08M last quarter. TTM EBITDA of $-13.02M and TTM operating income of $-18.67M show growth is flowing through to the bottom line. However, net income is negative at $34.33M — growth is not yet reaching the bottom line. Across the last 8 quarters, TTM revenue has risen for 7 consecutive quarters — an improving trend.

Margins

Gross, EBITDA, operating, and net margin trends

Gross Margin: 68.0%
EBITDA Margin: -3.6%
Op. Margin: -5.4%
Net Margin: -9.6%

Op. margin of -5.4% is up 9.3% YoY — cost efficiency is improving. Net margin at -9.6% and gross margin of 68.0% show how much of each revenue dollar survives to profit. Over the past year, operating margin is up 63% — an improving trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio: N/A
P/S Ratio: 1.7x
P/B Ratio: N/A

P/S of 1.7x and P/B of 0.0x. P/S is low relative to typical market levels.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets: $248.02M
Cash: $45.17M
Long-Term Debt: $156.74M
Book Value: $-30.90M
D/E Ratio: N/A
Debt/EBITDA: N/A

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow: $-3.59M
TTM Free Cash Flow: $-18.28M
FCF Margin: -5.8%
FCF / Net Income: 0.5

TTM FCF of $-18.28M on $-3.59M in operating cash flow. The FCF / Net Income ratio of 0.5x means cash covers only part of net income — earnings quality needs attention. Across the last 8 quarters, free cash flow has risen for 3 consecutive quarters — an improving trend.